AbCellera Biologics (ABCL)
(Delayed Data from NSDQ)
$3.01 USD
+0.04 (1.35%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $3.01 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth F Momentum F VGM
Balance Sheet
Fiscal Year End for AbCellera Biologics Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 786 | 911 | 748 | 594 | 8 |
Receivables | 31 | 39 | 161 | 213 | 3 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 56 | 75 | 21 | 6 | 2 |
Total Current Assets | 872 | 1,025 | 930 | 813 | 13 |
Net Property & Equipment | 288 | 217 | 112 | 18 | 8 |
Investments & Advances | 66 | 73 | 50 | 19 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 168 | 179 | 196 | 147 | 0 |
Deposits & Other Assets | 94 | 46 | 31 | 8 | 2 |
Total Assets | 1,488 | 1,541 | 1,319 | 1,006 | 23 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 50 | 33 | 32 | 20 | 3 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 2 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 19 | 23 | 27 | 0 |
Income Taxes Payable | 0 | 0 | 36 | 36 | 0 |
Other Current Liabilities | 69 | 66 | 30 | 20 | 3 |
Total Current Liabilities | 119 | 118 | 121 | 103 | 8 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 135 | 94 | 98 | 52 | 1 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 2 | 1 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 11 | 19 | 38 | 14 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 336 | 308 | 293 | 175 | 13 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 8 |
Common Stock (Par) | 753 | 734 | 722 | 710 | 5 |
Capital Surplus | 121 | 74 | 35 | 6 | 2 |
Retained Earnings | 280 | 426 | 268 | 114 | -5 |
Other Equity | -2 | -1 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 1,152 | 1,233 | 1,026 | 831 | 10 |
Total Liabilities & Shareholder's Equity | 1,488 | 1,541 | 1,319 | 1,006 | 23 |
Total Common Equity | 1,152 | 1,233 | 1,026 | 831 | 3 |
Shares Outstanding | 290.10 | 286.10 | 281.50 | 265.50 | NA |
Book Value Per Share | 3.97 | 4.31 | 3.64 | 3.13 | 0.00 |
Fiscal Year End for AbCellera Biologics Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 723 | 786 | 811 | 821 |
Receivables | NA | 34 | 31 | 37 | 46 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 57 | 56 | 71 | 64 |
Total Current Assets | NA | 814 | 872 | 920 | 931 |
Net Property & Equipment | NA | 306 | 288 | 277 | 260 |
Investments & Advances | NA | 72 | 66 | 63 | 59 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 167 | 168 | 172 | 175 |
Deposits & Other Assets | NA | 105 | 94 | 81 | 113 |
Total Assets | NA | 1,463 | 1,488 | 1,512 | 1,537 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 43 | 50 | 36 | 52 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 0 | 0 | 3 | 3 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 62 | 69 | 71 | 63 |
Total Current Liabilities | NA | 105 | 119 | 110 | 119 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 149 | 135 | 134 | 137 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 11 | 10 | 8 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 333 | 336 | 329 | 342 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 765 | 753 | 748 | 745 |
Capital Surplus | NA | 128 | 121 | 109 | 96 |
Retained Earnings | NA | 239 | 280 | 327 | 356 |
Other Equity | NA | -2 | -2 | -1 | -2 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 1,130 | 1,152 | 1,183 | 1,195 |
Total Liabilities & Shareholder's Equity | NA | 1,463 | 1,488 | 1,512 | 1,537 |
Total Common Equity | 0 | 1,130 | 1,152 | 1,183 | 1,195 |
Shares Outstanding | 294.00 | 293.90 | 290.10 | 290.10 | 288.70 |
Book Value Per Share | 0.00 | 3.84 | 3.97 | 4.08 | 4.14 |